Literature DB >> 20049835

Cancer incidence in people with AIDS in Italy.

Jerry Polesel1, Silvia Franceschi, Barbara Suligoi, Emanuele Crocetti, Fabio Falcini, Stefano Guzzinati, Marina Vercelli, Roberto Zanetti, Giovanna Tagliabue, Antonio Russo, Stefano Luminari, Fabrizio Stracci, Vincenzo De Lisi, Stefano Ferretti, Lucia Mangone, Mario Budroni, Rosa Maria Limina, Silvano Piffer, Diego Serraino, Francesco Bellù, Adriano Giacomin, Andrea Donato, Anselmo Madeddu, Susanna Vitarelli, Mario Fusco, Roberto Tessandori, Rosario Tumino, Pierluca Piselli, Luigino Dal Maso, Mauro Lise, Antonella Zucchetto, Angela De Paoli, Teresa Intrieri, Rosa Vattiato, Paola Zambon, Antonella Puppo, Silvia Patriarca, Andrea Tittarelli, Mariangela Autelitano, Claudia Cirilli, Francesco La Rosa, Paolo Sgargi, Enza Di Felice, Rosaria Cesaraccio, Francesco Donato, Silva Franchini, Loris Zanier, Fabio Vittadello, Pier Carlo Vercellino, Gennaro Senatore, Maria Lia Contrino, Silvia Antonini, Raffaele Palombino, Sergio Maspero, Maria Guglielmina La Rosa, Laura Camoni, Vincenza Regine.   

Abstract

People with HIV/AIDS (PWHA) have increased risk of some cancers. The introduction of highly active antiretroviral therapies (HAART) has improved their life expectancy, exposing them to the combined consequences of aging and of a prolonged exposure to cancer risk factors. The aim of this study was to estimate incidence rates (IR) in PWHA in Italy, before and after the introduction of HAART, after adjusting for sex and age through direct standardization. An anonymous record linkage between Italian AIDS Registry (21,951 cases) and Cancer Registries (17.3 million, 30% of Italian population) was performed. In PWHA, crude IR, sex- and age-standardized IR and age-specific IR were estimated. The standardized IR for Kaposi sarcoma and non-Hodgkin lymphoma greatly declined in the HAART period. Although the crude IR for all non-AIDS-defining cancers increased in the HAART period, standardized IR did not significantly differ in the 2 periods (352 and 379/100,000, respectively). Increases were seen only for cancer of the liver (IR ratio = 4.6, 95% CI: 1.3-17.0) and lung (IR ratio = 1.8, 95% CI: 1.0-3.2). Age-specific IRs for liver and lung cancers, however, largely overlapped in the 2 periods pointing to the strong influence of the shift in the age distribution of PWHA on the observed upward trends. In conclusion, standardized IRs for non-AIDS-defining cancers have not risen in the HAART period, even if crude IRs of these cancers increased. This scenario calls, however, for the intensification of cancer-prevention strategies, notably smoking cessation and screening programs, in middle-aged HIV-patients.

Entities:  

Mesh:

Year:  2010        PMID: 20049835     DOI: 10.1002/ijc.25153

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  28 in total

Review 1.  Impact of highly effective antiretroviral therapy on the risk for Hodgkin lymphoma among people with human immunodeficiency virus infection.

Authors:  James J Goedert; Mark Bower
Journal:  Curr Opin Oncol       Date:  2012-09       Impact factor: 3.645

Review 2.  Impact of antiretroviral therapy on the incidence of Kaposi's sarcoma in resource-rich and resource-limited settings.

Authors:  Aggrey S Semeere; Naftali Busakhala; Jeffrey N Martin
Journal:  Curr Opin Oncol       Date:  2012-09       Impact factor: 3.645

3.  A Population-Level Evaluation of the Effect of Antiretroviral Therapy on Cancer Incidence in Kyadondo County, Uganda, 1999-2008.

Authors:  Innocent Mutyaba; Warren Phipps; Elizabeth M Krantz; Jason D Goldman; Sarah Nambooze; Jackson Orem; Henry R Wabinga; Corey Casper
Journal:  J Acquir Immune Defic Syndr       Date:  2015-08-01       Impact factor: 3.731

4.  Cancer, immunodeficiency and antiretroviral treatment: results from the Australian HIV Observational Database (AHOD).

Authors:  K Petoumenos; M T van Leuwen; C M Vajdic; I Woolley; J Chuah; D J Templeton; A E Grulich; M G Law
Journal:  HIV Med       Date:  2012-08-30       Impact factor: 3.180

5.  Immunosenescence is associated with presence of Kaposi's sarcoma in antiretroviral treated HIV infection.

Authors:  Patrick Unemori; Kieron S Leslie; Peter W Hunt; Elizabeth Sinclair; Lorrie Epling; Ronald Mitsuyasu; Rita B Effros; Jeffrey Dock; Sheila G Dollard; Steven G Deeks; Jeffrey N Martin; Toby A Maurer
Journal:  AIDS       Date:  2013-07-17       Impact factor: 4.177

6.  Cutaneous manifestations of human immunodeficiency virus: a clinical update.

Authors:  Kirstin Altman; Erin Vanness; Ryan P Westergaard
Journal:  Curr Infect Dis Rep       Date:  2015-03       Impact factor: 3.725

7.  AIDS-associated Kaposi's sarcoma is linked to advanced disease and high mortality in a primary care HIV programme in South Africa.

Authors:  Kathryn M Chu; Gcina Mahlangeni; Sarah Swannet; Nathan P Ford; Andrew Boulle; Gilles Van Cutsem
Journal:  J Int AIDS Soc       Date:  2010-07-08       Impact factor: 5.396

8.  Immunophenotypical Switch versus Tumor Heterogeneity in a Patient with HIV-Associated Diffuse Large B-Cell Lymphoma.

Authors:  Jorge J Castillo; Tina Rizack; Diana Treaba
Journal:  Patholog Res Int       Date:  2010-10-05

Review 9.  The evolving scenario of non-AIDS-defining cancers: challenges and opportunities of care.

Authors:  Emanuela Vaccher; Diego Serraino; Antonino Carbone; Paolo De Paoli
Journal:  Oncologist       Date:  2014-06-26

Review 10.  Human immunodeficiency virus-associated lung malignancies.

Authors:  Allison A Lambert; Christian A Merlo; Gregory D Kirk
Journal:  Clin Chest Med       Date:  2013-04-08       Impact factor: 2.878

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.